CO2017004516A2 - Humanized anti-ox40 antibodies - Google Patents

Humanized anti-ox40 antibodies

Info

Publication number
CO2017004516A2
CO2017004516A2 CONC2017/0004516A CO2017004516A CO2017004516A2 CO 2017004516 A2 CO2017004516 A2 CO 2017004516A2 CO 2017004516 A CO2017004516 A CO 2017004516A CO 2017004516 A2 CO2017004516 A2 CO 2017004516A2
Authority
CO
Colombia
Prior art keywords
antibodies
humanized anti
methods
producing
cancer treatment
Prior art date
Application number
CONC2017/0004516A
Other languages
Spanish (es)
Inventor
Scott A Hammond
Michael Oberst
Qun Du
Melissa Damschroder
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of CO2017004516A2 publication Critical patent/CO2017004516A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La descripción proporciona anticuerpos anti-OX40 humanizados. También se proporcionan métodos de producir tales anticuerpos, y métodos de uso, p. ej., tratamiento del cáncer.The description provides humanized anti-OX40 antibodies. Also provided are methods of producing such antibodies, and methods of use, e.g. eg, cancer treatment.

CONC2017/0004516A 2014-10-10 2017-05-04 Humanized anti-ox40 antibodies CO2017004516A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062431P 2014-10-10 2014-10-10
PCT/US2015/054490 WO2016057667A1 (en) 2014-10-10 2015-10-07 Humanized anti-ox40 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2017004516A2 true CO2017004516A2 (en) 2017-09-29

Family

ID=55130798

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0004516A CO2017004516A2 (en) 2014-10-10 2017-05-04 Humanized anti-ox40 antibodies

Country Status (19)

Country Link
US (3) US9738723B2 (en)
EP (1) EP3204422B1 (en)
JP (2) JP6794348B2 (en)
KR (1) KR20170064550A (en)
CN (1) CN107074953A (en)
AR (1) AR102239A1 (en)
AU (1) AU2015328090A1 (en)
BR (1) BR112017007170A2 (en)
CA (1) CA2963798A1 (en)
CL (1) CL2017000885A1 (en)
CO (1) CO2017004516A2 (en)
ES (1) ES2914177T3 (en)
GB (1) GB2536324A (en)
IL (1) IL251537A0 (en)
MX (1) MX2017004715A (en)
RU (1) RU2709742C2 (en)
SG (1) SG11201702826XA (en)
TW (1) TW201619200A (en)
WO (1) WO2016057667A1 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687282T3 (en) 2013-03-18 2018-10-24 Biocerox Products B.V. ANTI-CD134 (OX40) humanized antibodies and their uses
US20150190506A1 (en) * 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
MA39817A (en) 2014-03-31 2017-02-08 Hoffmann La Roche Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CN115109158A (en) 2015-05-07 2022-09-27 阿吉纳斯公司 anti-OX 40 antibodies and methods of use thereof
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
LT3303396T (en) 2015-05-29 2023-01-10 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
AU2016329120B2 (en) 2015-10-02 2023-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory TNF receptor
US10624974B2 (en) 2015-10-15 2020-04-21 Dingfu Biotarget Co., Ltd. Anti-OX40 antibody and application thereof
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
AR108377A1 (en) 2016-05-06 2018-08-15 Medimmune Llc BISPECIFIC UNION PROTEINS AND ITS USES
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3030647A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
CN109963871A (en) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 Multivalence and multi-epitope Antibody and application method with agonist activity
MA46770A (en) 2016-11-09 2019-09-18 Agenus Inc ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
EP3725809A1 (en) 2016-12-15 2020-10-21 AbbVie Biotherapeutics Inc. Anti-ox40 antibodies and their uses
AU2017384528A1 (en) 2016-12-19 2019-07-04 Ichnos Sciences SA Novel TNFR agonists and uses thereof
CN110573528B (en) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 Bispecific antigen binding molecules to costimulatory TNF receptors
WO2018193104A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-cd25 antibody-drug conjugate
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
EP3704159A1 (en) * 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
MX2020005364A (en) * 2017-11-24 2020-08-13 Eucure Beijing Biopharma Co Ltd Anti-ox40 antibodies and uses thereof.
CN108218990B (en) * 2017-12-29 2021-03-02 南京优迈生物科技有限公司 Isolated antibodies or antigen binding fragments thereof and their use in tumor therapy
TWI742336B (en) * 2017-12-29 2021-10-11 圓祥生命科技股份有限公司 Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy, pharmaceutical composition, nucleic acid, and use thereof
CN111393529B (en) * 2018-01-29 2022-02-22 康源博创生物科技(北京)有限公司 anti-OX 40 antibodies that non-competitively bind to OX40L
CN111936507B (en) * 2018-03-23 2022-11-01 苏州丁孚靶点生物技术有限公司 OX40 antigen polypeptides and uses thereof
BR112020018539A2 (en) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company ANTIBODIES AGAINST MICA AND / OR MICB AND USES OF THE SAME
JP2021519298A (en) 2018-03-27 2021-08-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Real-time monitoring of titers using UV signals
BR112020023026A2 (en) 2018-05-11 2021-02-09 WuXi Biologics Ireland Limited fully human antibodies against ox40, a method for its preparation and use
AU2019272384A1 (en) * 2018-05-23 2021-01-07 Beigene, Ltd. Anti-OX40 antibodies and methods of use
JP2021524449A (en) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム Molecular adjuvant
WO2020014583A1 (en) 2018-07-13 2020-01-16 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
CN111040034B (en) * 2018-10-12 2022-08-30 广东旋玉健康生物科技有限公司 Monoclonal antibody of anti-human CD358 and application thereof
TW202028222A (en) 2018-11-14 2020-08-01 美商Ionis製藥公司 Modulators of foxp3 expression
EP3889180A4 (en) * 2018-11-26 2023-01-04 Nanjing GenScript Biotech Co., Ltd. Humanized anti-human ox40 monoclonal antibody, preparation method therefor and use thereof
WO2020119789A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
EP3904383A4 (en) * 2018-12-25 2022-08-17 Hanx Biopharmaceutics, Inc Anti-ox40 monoclonal antibody and application thereof
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
JP2022527272A (en) * 2019-03-25 2022-06-01 オハイオ・ステイト・イノベーション・ファウンデーション Combination immunomodulation and its use
EP3973274A1 (en) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Methods of monitoring cell culture media
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
KR20220016155A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy
CN114174537A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Cell localization features and combination therapies
WO2021098757A1 (en) * 2019-11-21 2021-05-27 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
WO2021098777A1 (en) * 2019-11-21 2021-05-27 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
WO2021098748A1 (en) * 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents
AU2020387990A1 (en) * 2019-11-21 2022-06-02 Beigene, Ltd. Methods of cancer treatment using anti-OX40 antibodies in combination with anti-TIM3 antibodies
BR112022009147A2 (en) * 2019-11-21 2022-07-26 Beigene Ltd METHODS OF TREATMENT OF CANCER AND METHODS TO INCREASE, POTENTIAL, OR STIMULATE AN IMMUNE RESPONSE OR FUNCTION
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
JP2023507115A (en) 2019-12-17 2023-02-21 アムジエン・インコーポレーテツド Dual interleukin-2/TNF receptor agonist for use in therapy
US20230139700A1 (en) 2020-03-23 2023-05-04 Bio-Thera Solutions, Ltd. Development and application of immune cell activator
WO2021228836A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with ox40 activating properties
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
KR20230080460A (en) 2020-10-05 2023-06-07 브리스톨-마이어스 스큅 컴퍼니 How to Concentrate Protein
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202241935A (en) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 Chimeric antigen receptor system with adaptable receptor specificity
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AU2022305518A1 (en) * 2021-06-29 2024-01-18 Hifibio, Inc. Anti-ox40 monoclonal antibody and methods of use thereof
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
CN114591988B (en) * 2022-03-30 2023-01-13 北京贝来生物科技有限公司 Preparation method of genetically modified stem cells for activating tumor immunity
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CN114966061B (en) * 2022-07-28 2022-10-21 中国食品药品检定研究院 Method for detecting biological activity of anti-OX 40 antibody
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
JP2003511012A (en) * 1999-09-24 2003-03-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 32 human secreted proteins
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
WO2006121810A2 (en) 2005-05-06 2006-11-16 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
TWI461436B (en) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
ES2546066T3 (en) * 2006-08-21 2015-09-18 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
JP2010518873A (en) * 2007-02-27 2010-06-03 ジェネンテック， インコーポレイテッド Antagonist anti-OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
KR101577843B1 (en) * 2007-12-14 2015-12-16 브리스톨-마이어스 스큅 컴퍼니 Binding molecules to the human ox40 receptor
WO2009092010A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
CA2713981C (en) 2008-02-08 2016-11-01 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
SG2014014708A (en) * 2009-02-17 2014-05-29 Ucb Pharma Sa Antibody molecules having specificity for human ox40
WO2013028231A1 (en) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
ES2634098T3 (en) * 2011-01-14 2017-09-26 The Regents Of The University Of California Therapeutic antibodies against the ROR-1 protein and procedures for their use.
JP6261499B2 (en) * 2011-07-11 2018-01-17 グレンマーク ファーマシューティカルズ， エセ．アー． Antibody binding to OX40 and use thereof
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
ES2740358T3 (en) 2012-02-06 2020-02-05 Providence Health & Services Oregon Method of monitoring cancer treatment with OX40 agonists
US20150157710A1 (en) * 2012-03-02 2015-06-11 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Dual ox40 agonist/il-2 cancer therapy methods
ES2687282T3 (en) * 2013-03-18 2018-10-24 Biocerox Products B.V. ANTI-CD134 (OX40) humanized antibodies and their uses

Also Published As

Publication number Publication date
KR20170064550A (en) 2017-06-09
RU2017115662A (en) 2018-11-13
BR112017007170A2 (en) 2017-12-19
US20190169303A1 (en) 2019-06-06
US9738723B2 (en) 2017-08-22
GB201517855D0 (en) 2015-11-25
WO2016057667A1 (en) 2016-04-14
GB2536324A (en) 2016-09-14
CL2017000885A1 (en) 2017-12-15
JP6794348B2 (en) 2020-12-09
RU2709742C2 (en) 2019-12-19
TW201619200A (en) 2016-06-01
SG11201702826XA (en) 2017-05-30
US10150815B2 (en) 2018-12-11
EP3204422A1 (en) 2017-08-16
ES2914177T3 (en) 2022-06-07
JP2021036887A (en) 2021-03-11
RU2017115662A3 (en) 2019-05-20
JP2017532037A (en) 2017-11-02
IL251537A0 (en) 2017-05-29
MX2017004715A (en) 2017-06-19
US20180072808A1 (en) 2018-03-15
US20160137740A1 (en) 2016-05-19
AR102239A1 (en) 2017-02-15
CA2963798A1 (en) 2016-04-14
CN107074953A (en) 2017-08-18
AU2015328090A1 (en) 2017-04-27
EP3204422B1 (en) 2022-03-30
EP3204422A4 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
CO2017004516A2 (en) Humanized anti-ox40 antibodies
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2017003022A (en) Anti-cll-1 antibodies and immunoconjugates.
NZ731467A (en) Anti-tim3 antibodies and methods of use
EA202092435A3 (en) MONOCLONAL ANTIBODIES AGAINST BCMA
GEP20217331B (en) Anti-tigit antibodies
EA201691991A1 (en) MULTI-SPECIFIC ANTIBODIES
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2017006694A (en) Fused bicyclic compounds for the treatment of disease.
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
MX2016015162A (en) Anti-gpc3 antibodies and immunoconjugates.
MX2017008456A (en) Fused bicyclic compounds for the treatment of disease.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018006249A (en) Novel anti-emr2 antibodies and methods of use.
EA201990370A1 (en) CANCER THERAPY ASSOCIATED WITH CREBBP
MX2018007817A (en) Novel anti-mmp16 antibodies and methods of use.
MX2018007818A (en) Novel anti-upk1b antibodies and methods of use.
EA202092450A2 (en) COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TUMOR TREATMENT